Nasdaq

Orchestra BioMed Hosts Symposium on Breakthrough AVIM Therapy for Uncontrolled Hypertension at HRS 2025 Annual Meeting

The FDA has granted Breakthrough Device Designation to Orchestra BioMed's Atrioventricular Interval Modulation (AVIM) therapy, aimed at treating patients with uncontrolled hypertension who are at ...
MedCity News

Orchestra BioMed’s Hypertension Device Wins FDA Breakthrough Designation

Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...
Business Insider

Orchestra BioMed announces data on atrioventricular interval modulation therapy

Orchestra BioMed (OBIO) announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation therapy on patients with diastolic dysfunction at the Technology and ...
Seeking Alpha

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...
Nasdaq

Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
The American Journal of Managed Care

Q&A: Novel Therapy Holds Promise for Hypertension Treatment in Patients With Pacemakers

Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers. For patients with pacemakers, hypertension is a common ...
Seeking Alpha

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Joint presentation by Orchestra BioMed (OBIO) and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled ...
BioWorld

Orchestra bioelectronics tune hypertension in pacemaker patients

Orchestra Biomed Holdings Inc. randomized the first patient in the BACKBEAT pivotal study investigating the use of its atrioventricular interval modulation (AVIM) therapy as a treatment for patients ...
TCTMD

Effects of AtrioVentricular Interval Modulation (AVIM) Therapy in Subjects With Hypertension and Diastolic Dysfunction

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...
Morningstar

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and ...

Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the ...
TCTMD

Neuromodulation by Atrioventricular Interval Modulation (AVIM) Therapy

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...